The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
Stephen Michael Keefe
Research Funding - Cerulean Pharma
Daniel Heitjan
No relevant relationships to disclose
Meliessa Hennessey
Employment or Leadership Position - Cerulean Pharma
Janelle Robinson
Research Funding - Cerulean Pharma
Kristine Mykulowicz
Research Funding - Cerulean Pharma
Amy Marshall
Research Funding - Cerulean Pharma
Orvar Gunnarsson
No relevant relationships to disclose
Ronac Mamtani
No relevant relationships to disclose
David J. Vaughn
No relevant relationships to disclose
Jean H. Hoffman-Censits
No relevant relationships to disclose
Katherine L. Nathanson
No relevant relationships to disclose
Priti Lal
No relevant relationships to disclose
Daniel A. Pryma
No relevant relationships to disclose
Scott Eliasof
Employment or Leadership Position - Cerulean Pharma
Edward Graeme Garmey
Employment or Leadership Position - Cerulean Pharma
Roger B. Cohen
Consultant or Advisory Role - Cerulean Pharma
Naomi B. Haas
Research Funding - Cerulean Pharma